Determinants of newly diagnosed comorbidities among breast cancer survivors

Journal of Cancer Survivorship

Volumn 8, Issue 3, 2014, Pages 384-393

  Obi, Nadia ^a   Gornyk, Daniela ^a   Heinz, Judith ^a   Vrieling, Alina ^b,c   Seibold, Petra ^b   Chang Claude, Jenny ^b   Flesch Janys, Dieter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aromatase inhibitor; Breast cancer survivors; Comorbidity; Hypertension; Osteoporosis; Trastuzumab

Indexed keywords

AROMATASE INHIBITOR; MONOCLONAL ANTIBODY; TRASTUZUMAB;

AGED; BODY MASS; BREAST TUMOR; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMORBIDITY; COMPLICATION; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; OSTEOPOROSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; SURVIVOR;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVORS;

EID: 84905722506     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-013-0338-y     Document Type: Article

References (43)

1. American Cancer Society. Cancer facts & figures 2012. Atlanta: American Cancer Society 2012.
2. Cancer survival in England: Patients diagnosed 2005-2009 and followed up to 2010. Office for National Statistics (ONS). London, 2011. http://www. ons. gov. uk/ons/publications/re-reference-tables. html?edition=tcm%3A77-239726#tab-all-tables. Accessed 9 Mar 2013.
3. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci. 2003;58(1): 82-91.
4. Girones R, Torregrosa D, Díaz-Beveridge R. Comorbidity, disability and geriatric syndromes in elderly breast cancer survivors. Results of a single-center experience. Crit Rev Oncol Hematol. 2010;73(3): 236-45.
5. Rao AV, Demark-Wahnefried W. The older cancer survivor. Crit Rev Oncol Hematol. 2006;60(2): 131-43.
6. Land LH, Dalton SO, Jorgensen TL, Ewertz M. Comorbidity and survival after early breast cancer. A review. Crit Rev Oncol/Hematol. 2012;81(2): 196-205.
7. Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst. 2011;103(14): 1101-11.
8. Newschaffer CJ, Bush TL, Penberthy LT. Comorbidity measurement in elderly female breast cancer patients with administrative and medical records data. J Clin Epidemiol. 1997;50(6): 725-33.
9. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98(9): 1802-10.
10. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17): 1299-309.
11. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24): 2504-12.
12. Harlan LC, Klabunde CN, Ambs AH, et al. Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer. J Cancer Surviv. 2009;3(2): 89-98.
13. Khan NF, Mant D, Carpenter L, Forman D, Rose PW. Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study. Br J Cancer. 2011;105 Suppl 1: S29-37.
14. Flesch-Janys D, Slanger T, Mutschelknauss E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer. 2008;123(4): 933-41.
15. Schmidt ME, Chang-Claude J, Vrieling A, et al. Association of pre-diagnosis physical activity with recurrence and mortality among women with breast cancer. Int J Cancer. 2013;133(6): 1431-40.
16. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16(11): 1330-8.
17. Isidoro B, Lope V, Pedraz-Pingarron C, et al. Validation of obesity based on self-reported data in Spanish women participants in breast cancer screening programmes. BMC Public Health. 2011;11: 960.
18. Spencer EA, Appleby PN, Davey GK, Key TJ. Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr. 2002;5(4): 561-5.
19. Li J, Siegrist J. Physical activity and risk of cardiovascular disease-a meta-analysis of prospective cohort studies. Int J Environ Res Public Health. 2012;9(2): 391-407.
20. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol. 2009;20(8): 1319-29.
21. Ligibel JA, James OA, Fisher M, Daniel GW, Winer EP, Keating NL. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Breast Cancer Res Treat. 2012;131(2): 589-97.
22. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23(22): 5126-37.
23. Geisler J, Lonning PE. Impact of aromatase inhibitors on bone health in breast cancer patients. J Steroid Biochem Mol Biol. 2010;118(4-5): 294-9.
24. Cheung AM, Tile L, Cardew S, et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP. 3 randomised controlled trial. Lancet Oncol. 2012;13(3): 275-84.
25. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. The Lancet Oncology. 2006;7(8): 633-43.
26. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007;25(36): 5715-22.
27. McCaig F, Renshaw L, Williams L, et al. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2010;119(3): 643-51.
28. Untch M, Jackisch C, Thomssen C, Nitz U, von Minkwitz G, Kaufmann M. Adjuvant treatment with trastuzumab in patients with breast cancer. Dtsch Arztebl. 2006;103(50): 3406-10.
29. Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3): 236-44.
30. Hysing J, Wist E. Cardiotoxic effects of trastuzumab. Tidsskr Nor Laegeforen. 2011;131(22): 2239-41.
31. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4): 300-11.
32. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. The Lancet, published online 18-7-2013.
33. Bowles EJA, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. JNCI. 2012;104(17): 1293-305.
34. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31): 3792-9.
35. Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer. 2012;118(8 Suppl): 2270-6.
36. Harris EER, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006;24(25): 4100-6.
37. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11): 937-47.
38. Slanger T, Mutschelknauss E, Kropp S, Braendle W, Flesch-Janys D, Chang-Claude J. Test-retest reliability of self-reported reproductive and lifestyle data in the context of a German case-control study on breast cancer and postmenopausal hormone therapy. Ann Epidemiol. 2007;17(12): 993-8.
39. Silliman RA, Lash TL. Comparison of interview-based and medical-record based indices of comorbidity among breast cancer patients. Med Care. 1999;37(4): 339-49.
40. Kriegsman DM, Penninx BW, van Eijk JT, Boeke AJ, Deeg DJ. Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients' self-reports and on determinants of inaccuracy. J Clin Epidemiol. 1996;49(12): 1407-17.
41. Fuchs J, Busch M, Lange C, Scheidt-Nave C. Prevalence and patterns of morbidity among adults in Germany. Results of the German telephone health interview survey German Health Update (GEDA) 2009. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012;55(4): 576-86.
42. Moebus S, Hanisch J, Aidelsburger P, Bramlage P, Wasem J, Jockel KH. Impact of 4 different definitions used for the assessment of the prevalence of the metabolic syndrome in primary healthcare: the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol. 2007;6(1): 22.
43. Garriguet D. Bone health: osteoporosis, calcium and vitamin D. Health Rep. 2011;22(3): 7-14.